Trials / Completed
CompletedNCT04823702
Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function
A Phase I, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Aldafermin in Subjects With Impaired Hepatic Function
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- NGM Biopharmaceuticals, Inc · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
This is an evaluation of Aldafermin (NGM282) in an open-label, single-dose and parallel group study in participants with Impaired Hepatic Function
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Aldafermin | Biological: Aldafermin (NGM282) Subcutaneous Injection |
Timeline
- Start date
- 2021-04-01
- Primary completion
- 2021-11-19
- Completion
- 2021-11-19
- First posted
- 2021-04-01
- Last updated
- 2022-01-19
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04823702. Inclusion in this directory is not an endorsement.